Brief: Mineralys Therapeutics Announces Mid-Stage Study Of Lorundrostat For Obstructive Sleep Apnea In Patients With Hypertension
08/01/2025 14:01
Jan 8 (Reuters) - Mineralys Therapeutics Inc MLYS.O :
* MINERALYS THERAPEUTICS ANNOUNCES PHASE 2 CLINICAL TRIAL OF
LORUNDROSTAT FOR OBSTRUCTIVE SLEEP APNEA IN PATIENTS WITH
HYPERTENSION
* MINERALYS THERAPEUTICS INC - TO INITIATE PHASE 2 TRIAL IN
Q1
2025
* MINERALYS THERAPEUTICS INC - EXPECTS FUNDS TO SUPPORT
OPERATIONS
THROUGH Q1 2026
* MINERALYS THERAPEUTICS INC - PRIMARY OUTCOME MEASURE IS
CHANGE
IN APNEA-HYPOPNEA EPISODES
Source text: urn:newsml:reuters.com:*:nGNXbGrlRN
Further company coverage: MLYS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mineralys Therapeutics
See all newsBrief: Mineralys Therapeutics Expands Its Board Of Directors With The Appointments Of Kristine Peterson And Lonnel Coats
Mineralys Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway